Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Sees Large Increase in Short Interest

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) was the target of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 1,370,000 shares, an increase of 24.5% from the December 31st total of 1,100,000 shares. Based on an average daily volume of 9,200,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 7.9% of the shares of the company are sold short.

Insider Buying and Selling at Syros Pharmaceuticals

In other news, Director Nancy A. Simonian sold 134,713 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $0.27, for a total transaction of $36,372.51. Following the sale, the director now directly owns 41,070 shares of the company’s stock, valued at $11,088.90. This represents a 76.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 12.26% of the company’s stock.

Institutional Investors Weigh In On Syros Pharmaceuticals

An institutional investor recently bought a new position in Syros Pharmaceuticals stock. GSA Capital Partners LLP bought a new position in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 15,905 shares of the company’s stock, valued at approximately $34,000. GSA Capital Partners LLP owned approximately 0.06% of Syros Pharmaceuticals at the end of the most recent quarter. 91.47% of the stock is currently owned by hedge funds and other institutional investors.

Syros Pharmaceuticals Stock Performance

Shares of Syros Pharmaceuticals stock traded up $0.01 during trading hours on Friday, reaching $0.18. 971,418 shares of the company were exchanged, compared to its average volume of 1,709,868. The firm has a market cap of $4.70 million, a PE ratio of -0.06 and a beta of 1.31. Syros Pharmaceuticals has a 1 year low of $0.16 and a 1 year high of $7.96. The stock’s fifty day moving average is $0.22 and its 200 day moving average is $1.77.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.08. During the same period in the previous year, the company posted ($1.35) EPS. Research analysts expect that Syros Pharmaceuticals will post -2.94 earnings per share for the current year.

Analyst Ratings Changes

SYRS has been the subject of several recent analyst reports. TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. HC Wainwright reiterated a “neutral” rating and set a $1.00 price target (down previously from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. StockNews.com initiated coverage on shares of Syros Pharmaceuticals in a research note on Saturday. They issued a “sell” rating on the stock. Finally, JMP Securities reaffirmed a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $3.33.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.